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Posttransplantation chronic renal damage in nonrenal trans-
plant recipients.
Background. The growing problem of relentless deteriora-
tion of renal function in patients who undergo transplantation
of nonrenal solid organs is bound to have an increasingly im-
portant impact as it may not only worsen patient morbidity and
mortality but also increase transplantation costs.
Methods. We reviewed the literature in order to provide a
sum of the most important data on the incidence, clinical picture,
renal pathology pattern, damage mechanisms, and risk factors,
along with strategies for prevention and treatment of chronic
renal damage following nonrenal solid organ transplantation.
Results. Literature data report that 10% to 80% of trans-
planted patients have some degree of renal dysfunction and that
they share a common clinical picture characterized by relentless
asymptomatic progression, frequent hypertension, mild urinary
abnormalities, and pathology features of vascular, glomerular,
tubular, and interstitial involvement. These changes are very
similar to those reported for chronic nephrotoxicity from cal-
cineurin inhibitors. The occurrence of end-stage renal disease
(ESRD) requiring chronic dialysis has been reported in up to
20% of nonrenal transplant recipients. Although there are some
organ-specific differences, a group of common risk factors has
been recognized, including the use of calcineurin inhibitors as
immunosuppressive agents, age, pretransplantation renal func-
tion, intraoperative/perioperative factors, concomitant use of
other nephrotoxic drugs, infections, and posttransplantation
acute renal failure.
Conclusion. Calcineurin inhibitor–induced nephrotoxicity is
a growing problem and, as the age of recipients of nonrenal or-
gans is increasing, this problem is destined to increase. It would
therefore be advisable for nephrologists to share their expe-
riences in immunomodulation with other specialties, so as to
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favor the cautious extension of calcineurin inhibitor–sparing
protocols to the area of life-saving transplants.
The current “revolution” in the field of organ trans-
plantation earmarks a new era for medicine. However,
there is a growing awareness that chronic renal failure,
eventually leading to end-stage renal disease (ESRD)
requiring chronic dialysis, poses a serious threat to non-
renal organ transplant patients. Although previous data
suggested a self-limited decrease in renal function in the
absence of overt effects on patient outcomes [1], more
recent studies performed on large samples of recipients
of nonrenal transplants have shown that this is clearly
not the case [2–5]. On the contrary, complications aris-
ing from nonrenal transplants significantly increase the
risk of renal failure and rates of morbility and mortal-
ity in patients [4, 5]. Reports show that nonrenal trans-
plant patients with chronic renal failure have a twofold
higher risk of mortality than patients without chronic re-
nal failure. Moreover, the presence of ESRD requiring
chronic dialysis has been associated with an even higher
risk of death (relative risk 4.55; 95% CI 4.38 to 4.74)
(P < 0.01) [4]. Therefore, if we consider the potential
impact on public health services of such complications in
a large cross-section of patients, the need for strategies
capable of preventing and minimizing renal damage after
transplantation of nonrenal organs becomes clear.
This review analyzes the incidence of the problem, its
clinical picture, renal pathology pattern, damage mecha-
nisms and risk factors, along with strategies for preven-
tion and treatment.
EPIDEMIOLOGIC DATA
It is estimated that more than 100,000 nonrenal solid
organ transplants are carried out each year in the fol-
lowing order of frequency: liver (over 50%), heart, lung,
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Table 1. Synopsis of the main epidemiologic studies on cumulative
incidence of end-stage renal disease (ESRD) requiring maintenance
dialysis in nonrenal organ transplant recipients, according to type of
organ
Number Median ESRD
Author of follow-up incidence
Year [reference] patients years %
Liver
1995 Naumann et al [6] 104 6.5 8.6
1998 Fisher et al [7] 883 4.3 1.4
2001 Gonwa et al [8] 834 13 5.4
2001 Lynn et al [9] 132 5 3.4
2002 Cohen et al [10] 353 10 10
2003 Pawarode et al [11] 172 6 7
2003 Moreno et al [12] 289 5.3 4.1
Heart
1990 Greenberg et al [13] 228 7 2.2
1991 Lewis et al [14] 100 4 1
1992 Gonwa et al [15] 69 4 1.3
1994 Zietse et al [16] 187 5 3.2
1997 Tinawi et al [17] 133 5 0
1997 Goral et al [18] 39 6 4
1997 Goldstein et al [19] 293 10 6.5
1998 Van Gelder et al [20] 304 6.6 8
2000 Lindelow et al [21] 151 9 4
2002 Satchithananda et al [22] 697 6 5.8
2003 Garrido et al [23] 262 5 0.9
2004 Rubel et al [24] 370 10 20.3
Lung
1999 Wilkinson et al [2] 126 8 1.6
2000 Tsimaratos et al [25] 19 5.3 5
Heart-lung
1995 Pattison et al [1] 100 4 3
lung-heart, and intestine. A distinction must be made
between low/mild degrees of renal damage, advanced
chronic renal failure and ESRD patients requiring main-
tenance dialysis so as to correctly assess the incidence of
renal impairment in these cases.
Reports of the incidence of chronic renal disease range
from 10% to 83%, but this marked difference is due to
the different criteria used to define renal dysfunction [4].
Results in the largest most recent study of transplant
patients, where severe chronic renal failure is defined as
creatinine clearance equal to or below 29 mL/min per 1.73
m2 of body surface area, are as follows: 16.5% (average
value) liver (18%), heart (11%), lung (16%), heart-lung
(7%), and intestine (21%) after a median follow-up of
36 months. The cumulative incidence of ESRD was 4.7%
(3297/69,321 recipients) which is equal to 1% to 1.5%
new cases per year [4].
Table 1 shows a synopsis of main studies on the rate
of ESRD in the different types of nonrenal transplant
recipients [2, 6–25]. ESRD cumulative incidence appears
to range from 1.4% to 10% for liver transplants [8, 10,
12] and from 0% up to 23% for heart transplants [19,
20, 22, 24]. A lower incidence has been reported for lung
transplants (1.6% to 5%) after a slightly shorter median
follow-up [2]. We found only one large study on ESRD
in heart-lung transplants, which reported severe chronic
renal failure in 3% of transplant patients after 4 years [1].
No specific studies on ESRD in intestine transplants were
available, probably due to the fact that patients belong to
a lower age group and the relatively smaller number of
cases.
Clinical picture
Patients who receive nonrenal transplantation usually
have normal or only mildly impaired renal function at the
time of transplantation, although serum creatinine levels
can be misleading in malnourished patients with liver or
heart failure. The clinical course from transplantation to
ESRD ranges from rapid deterioration to slow progres-
sion with long periods of functional stability. However,
the clinical picture in the recipients developing ESRD is
similar [2], regardless of the type of organ transplant.
The most frequent pattern shows a biphasic curve, with
a 50% decrease in the glomerular filtration rate (GFR)
during the first 12 months after transplant, followed by
stabilization and a subsequent slow but relentless decline
until ESRD. Some authors warn that, during the second
“stabilization” phase, renal function is preserved at the
price of progressive hyperfiltration and irreversible struc-
tural renal damage progresses, even in the presence of
stable serum creatinine values [26].
Even if increased proteinuria can occur as a conse-
quence of this process, it is usually only about 1 g/day.
When the increase is detected, it is usually associated with
advanced chronic renal failure. It can also be a marker
of other glomerular diseases, especially when it occurs
with normal renal function. These include focal glomeru-
lar sclerosis after heart transplantation [2, 27] and IgA
nephropathy, membranous and membranoproliferative
glomerulonephritis after liver transplantation [2, 9]. The
urinary sediment is usually unremarkable and abnormali-
ties should again give rise to the suspicion of an associated
glomerulonephritis; in liver transplantation hepatorenal
syndrome is another differential diagnosis; indeed, kid-
ney biopsy is advocated by some authors in these cases
[2]. Hypertension accompanying the progression of renal
dysfunction is common (65% to 85% in liver transplanted
patients, 90% in heart, and 60% to 70% in lung) even if
most patients were not hypertensive at the time of trans-
plantation [2].
Hyperkalemic distal renal tubular acidosis (type IV)
has been described with cyclosporine A (CsA) and
tacrolimus therapy [28].Thrombotic microangiopathy is a
less common expression of calcineurin inhibitor nephro-
toxicity. The spectrum of thrombotic microangiopathy
manifestations ranges from graft-limited forms, which
can be diagnosed only through renal biopsy, to the full-
blown picture of de novo hemolytic-uremic syndrome
(HUS) and thrombotic thrombocytopenic purpura [29].
Prognosis of these systemic forms is poor, with nearly
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Fig. 1. Renal biopsy in a 48-year-old woman
with liver transplant, who had been biopsied
due to worsening of chronic renal failure 6
months after liver transplantation. Light mi-
croscopy [periodic acid-Schiff (PAS) 125×].
The morphologic feature was characterized
by diffuse fibrosis with tubular atrophy and is-
chemic damage of glomeruli some with global
sclerosis and some others showing collapsed
tuft.
half of affected patients losing their transplanted kidney.
CsA-induced HUS has also been described in association
with hemorrhagic colitis [30].
All nephrotoxicity manifestations can occur even with
very low CsA [31] and tacrolimus [32] levels and sig-
nificant recovery of renal function can be achieved
with calcineurin inhibitor discontinuation in these
situations.
PATHOLOGY
Most data come from autopsy studies, as biopsies
are more rarely reported. Pathologic damage has been
observed in all portions of the nephron, including oblit-
erative vasculopathy (characterized by arteriolar focal
hyalinosis, myocyte necrosis, nodular hyaline deposits,
and intimal edema). This primarily involves afferent ar-
terioles and perhaps represents the most important le-
sion as it may result in irreversible damage affecting
all the other nephron sectors causing ischemia, sclerosis,
and collapse of glomeruli, tubular atrophy, and intersti-
tial fibrosis. Globally, the picture closely resembles that
observed in patients receiving CsA for the treatment of
autoimmune diseases [33–35]. However, even if there are
common features, renal damage in transplanted patients
on CsA can vary significantly.
Organ-specific pictures
Liver. The aforementioned pathologic damage is
common in liver transplant patients. Interstitial fibrosis
is frequent and it increases progressively with exposure
to CsA and the total dose administered [36, 37]. Our ex-
perience confirmed the presence of diffuse interstitial fi-
brosis in a 48-year-old woman with liver transplant, who
had been biopsied due to a worsening of chronic re-
nal failure 6 months after the transplantation. Although
histology showed tubular and interstitial damage, the
prominent feature was the ischemic damage of glomeruli
(Fig. 1). Laboratory tests showed an increase in serum
creatinine from a pretransplant value of 1.6 mg/dL to
3.5 mg/dL at the moment of renal biopsy. Maintenance
immunosuppressive therapy was based on CsA, steroids,
azathioprine; CsA had been substituted for tacrolimus a
few weeks before biopsy.
Glomerular abnormalities were also found to be more
frequent in liver transplant recipients than in other types
of transplant patients. This depends on pretransplan-
tation glomerular diseases such as IgA nephropathy,
membranous nephropathy, membranoproliferative
glomerulonephritis, and focal segmental glomeruloscle-
rosis [2, 36–38].
Heart. Pioneer studies demonstrated that heart trans-
plant patients suffered from both a depression of the
GFR and a variable degree of tubulointerstitial injury,
accompanied by focal glomerular sclerosis. This was most
commonly observed in patients treated with CsA than in
those with azathioprine with equivalent cardiac output
[39]. Bertani, Ferrazzi, and Schieppati [39] compared the
histology of patients who died from congestive heart fail-
ure with that of cardiac transplant recipients, and demon-
strated that the heart failure group showed none of the
structural abnormalities found in the cardiac transplant
group. This finding confirmed that most lesions in the re-
nal biopsies of cardiac transplant recipients were caused
by events occurring after transplantation and were there-
fore independent of cardiac factors.
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Other studies suggested that early CsA damage is a
form of thrombotic microangiopathy with focal glomeru-
lar and/or arteriolar thrombosis evolving into CsA arte-
riolopathy and subsequently interstitial fibrosis [40, 41],
or an early preglomerular arteriolar involvement even-
tually leading to glomerular obliteration by a progressive
increase in renal arteriolar hyalinosis and a higher num-
ber of glomeruli affected by global sclerosis, both corre-
lated with the duration of exposure to CsA and the total
dosage [42]. Furthermore, many cardiac transplant recip-
ients develop a prominent segmental glomerulosclerosis
which results in severe renal insufficiency and heavy pro-
teinuria [27].
Lung. Zaltsman et al [43] and Paller et al [44] analyzed
renal biopsies from a group of heart, lung, or heart and
lung transplant recipients on CsA therapy and grouped
their histopathologic findings into three categories: se-
vere vascular and glomerular lesions due to thrombotic
microangiopathy, a form of focal segmental glomeru-
losclerosis and glomerular ischemia. These alterations ap-
peared to be part of the spectra of pathologies, all of which
coexisted in some biopsies. In focal segmental glomeru-
losclerosis, monitoring of urinary protein proved useful
because the onset of proteinuria usually precedes func-
tional impairment.
PATHOPHYSIOLOGY, MECHANISMS OF
DAMAGE, AND RISK FACTORS
All the studies reporting renal impairment after non-
renal transplantation included patients treated with CsA
and tacrolimus, better known as calcineurin inhibitors.
Their introduction into clinical practice, in the early 1980s,
raised the 1-year survival rate for renal allografts from
60% to 80% to 90%. Besides the aforementioned bene-
fits, the use of calcineurin inhibitors provided a cure for
some autoimmune diseases. However, nephrotoxicity re-
mains the main complication for patients treated with
these drugs, as the same immunosuppression mechanism
is also responsible for their nephrotoxicity. Records dat-
ing back to the pioneer studies carried out 20 years ago
clearly show that the excess risk of chronic renal fail-
ure in nonrenal transplant recipients is mainly related to
the adoption of calcineurin inhibitor immunosuppressive
agents [45].
A comparative study of heart transplant patients
treated with azathioprine or CsA was carried out by
Myers, Newton, and Boshkos [46] in 1988. It was demon-
strated that, although both groups had the same cardiac
output, both the GFR and renal plasma flow were de-
pressed in the CsA group, which showed a trend toward a
restricted transglomerular transport of neutral dextrans.
This suggested an intrinsic loss of ultrafiltration capacity
by glomerular capillaries rather than a simple hemody-
namic mechanism [46].
Even if most studies on calcineurin inhibitors dos-
ing and levels do not predict renal damage, rather sug-
gesting independent individual susceptibility traits, when
trough levels and daily dose (mg/kg) at various times after
transplantation are considered, a weak correlation does
emerge between increased exposure and the risk of im-
paired renal function [2].
So, the negative calcineurin inhibitor influence has
been implicated as being largely responsible for chronic
renal failure also in nonrenal transplant recipients, al-
though peculiar mechanisms and organ-specific risk fac-
tors must be taken into account.
An in-depth review of the mechanisms leading to cal-
cineurin inhibitor–mediated nephrotoxicity is beyond the
scope of this review.
In summary, calcineurin inhibitor–mediated nephro-
toxicity is the result of hemodynamic and direct cellu-
lar effects on vascular endothelium and tubular epithe-
lium. Indeed, functional nephrotoxicity is essentially due
to a vasoconstriction of preglomerular afferent arteri-
oles and is triggered by an increased sympathetic tone,
activation of the renin-angiotensin system, an altered
balance between thromboxane and prostaglandins, an in-
creased production of endothelin-1, and a decreased pro-
duction of nitric oxide by endothelial cells. Calcineurin
inhibitors also exert a direct toxic effect on endothelial
and tubular cells, which may contribute to the release
of various vasoactive compounds. Calcineurin inhibitor–
induced vasoconstriction is dose-related and determines
chronic renal ischemia, which consequently triggers acti-
vation of the renin-angiotensin system and an increased
transforming growth factor-b (TGF-b) synthesis as well
as other fibrogenic mediators. This process results in in-
terstitial fibrosis leading to chronic renal failure [47, 48].
Calcineurin inhibitor-nephrotoxicity in native kidneys
versus renal allografts
What are the main potential differences between cal-
cineurin inhibitor-nephrotoxicity in native kidneys and in
renal allografts? The comparison between the impact of
nephrotoxicity on nonrenal and renal transplant patients
is a difficult task, as the factors to be considered are many
and varied [2, 3, 49, 50].
From a pathogenetic point of view, the most intriguing
aspect is that transplanted kidneys lack the sympathetic
innervation, whereas native kidneys of nonrenal trans-
plant recipients have to pay for sympathetic stimulation,
which is one of the main mechanisms involved in cal-
cineurin inhibitor–induced renal vasoconstriction. On the
other hand, they are not prone to the immune-mediated
components of chronic rejection, which compound the
effects of nephrotoxicity [47] (Fig. 2).
From a morphologic point of view, some subtle differ-
ences in renal pathology may be observed at the matrix
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Fig. 2. Mechanisms of damage for trans-
planted and native kidneys in renal trans-
planted and nonrenal transplanted patients.
Calcineurin inhibitor (CNI)-nephrotoxicity is
shared as the same insult on different targets.
ARF is acute renal failure.
protein level [51]. A prevalence of ischemic damage over
interstitial lesions has also been observed and may be the
consequence of some of the pathogenic differences. It is
tempting to speculate that the noxious hemodynamic cal-
cineurin inhibitor effects might be enhanced by a normal
sympathetic innervation and aggravate ischemic damage
in native kidneys [51].
Risk factors other than calcineurin
inhibitor-nephrotoxicity
There are other variables that could contribute to renal
dysfunction (Table 2).
First, complications arising from the transplantation
procedure itself may play a decisive role in a subsequent
development of ESRD. A particularly significant risk fac-
tor is the early occurrence of acute renal failure following
transplantation. This may be due to a variety of factors
that can be classified into three categories: preoperative,
intraoperative, and perioperative settings. Preoperative
renal status includes intrarenal hemodynamic changes,
such as hepatorenal syndrome in liver transplant recip-
ients and severe hypoperfusion from cardiac failure in
heart transplant recipients; the intraoperative conditions
include hypotension, hemorrhage, and hemolysis due to
extracorporeal circulation in heart transplants; and pe-
rioperative factors include hemodynamic instability, in-
fection (cytomegalovirus), sepsis, or effects of pressure
agents or other drugs, such as nephrotoxic antibiotics or
continuous intravenous CsA [2].
Second, organ-specific peculiarities, including pre-
transplantation renal status, also play an important role.
Liver transplant recipients, for instance, tend to have pre-
existing glomerular diseases, due to inadequate clearance
of immunocomplexes caused by liver disease [2, 9, 10].
Table 2. General risk factors for developing progressive renal
insufficiency in nonrenal transplanted patients
Setting Risk factor
Preoperative Age
Gender
Race
Genetic factors
Pretransplant renal status
Preexisting renal diseases due to subcategories of
organ-specific transplants
Chronic renal failure [glomerular filtratration rate
(GFR) <90 mL/min]
Dialysis treatment before transplantation
Hypertension
Hyperlipidemia
Diabetes mellitus
Hepatitis C virus positivity
Retransplantation
Intraoperative Acute renal failure
Need for dialysis
Hypotension
Use of pressor agents
Postoperative Acute renal failure
Sepsis
Cytomegalovirus infection
Calcineurin inhibitor exposure
Long-term Renal function at 1 year
Hypertension
Proteinuria
Hyperlipidemia
Infections
Calcineurin inhibitor exposure
Furthermore, other contributing factors may be due
to subcategories of diseases within organ-specific trans-
plants. For example, in the setting of liver disease
hepatitis C infection can be associated with vari-
ous glomerulonephritides [52]. This form of immune-
mediated damage will not be present if the cause of
end-stage liver disease is, for example, Caroli disease [2].
According to the study by Ojo et al [4], a positive serologic
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Fig. 3. Relative risks of chronic renal failure
in different nonrenal transplanted patients ac-
cording to the presence of different risk fac-
tors (modified from [4]). Risk factors are:
age categorized as per 10-year increments,
pretransplantation glomerular filtration rate
(GFR) between 59 and 30 mL/min and ≤29
mL/min as compared to ≥90 mL/min as ref-
erence group, postoperative acute renal fail-
ure (ARF) defined as 50% reduction from
baseline in the GFR or a need for dialysis
treatment during the initial hospitalization for
transplantation, cyclosporine used during ini-
tial hospitalization, hypertension (hyper) cat-
egorized as previous diagnosis before trans-
plantation, diabetes before transplantation,
hepatitis C virus (HCV) seropositivity before
transplantation, 1990 to 1993 as the period
during which transplantation was performed
as compared to 1998 to 2000 as reference
group.
result for hepatitis C before transplantation was closely
associated with an increased risk of chronic renal failure,
except for recipients of lung transplants.
There are factors in the heart transplant patients, such
as an underlying diagnosis of ischemic cardiomyopathy at
the time of transplantation, which seem to contribute to
the development of chronic renal failure, as this manifes-
tation of atherosclerotic vascular disease usually parallels
ischemic renal status [2, 19].
Lung transplant patients at risk include those with pul-
monary hypertension and chronic obstructive pulmonary
disease, who have a significantly better prognosis than
patients with cystic fibrosis, despite normal pretransplant
renal function. The increased risk for this subgroup is ex-
plained by several factors, including the fact that most
cystic fibrosis patients have usually had previous expo-
sure to aminoglycoside antibiotics and have experienced
preexistent renal tubular function disorders or microcal-
cinosis, secondary amyloidosis, and diabetes mellitus [53].
Finally, another aspect which must not be forgotten is
that of patient-specific factors which contribute to a wors-
ening of renal damage, whether genetic (TGF-b genetic
polymorphisms seem to contribute to the development
of ESRD in heart transplant recipients) [54], or acquired
(hypertension, dyslipemia, or hyperuricemia).
Summing up, apart from patient-specific and organ-
specific susceptibility traits, there is a common group of
risk factors which lead to ESRD in recipients of any type
of nonrenal transplant (Table 2). Common potential con-
tributors to the progression of chronic renal failure in pa-
tients who have received any type of transplantation are
age, gender, year of transplantation, diabetes mellitus,
hypertension, creatinine clearance of 29 mL/min prior to
renal transplantation or preexisting renal diseases, hep-
atitis C infection, postoperative acute renal failure, hyper-
lipidemia, and nephrotoxic drugs [2, 4, 7, 55]. Although
their prevalence and importance appears to vary accord-
ing to the type of transplanted organ (Fig. 3), they are all
independent variables which increase the risk of progres-
sion to ESRD. In Figure 3, according to the corresponding
reference, risk factors are age, categorized as per 10 years’
increment, pretransplantation GFR between 59 and
30 mL/min and ≤29 mL/min as compared to ≥90 mL/min
as reference group, postoperative acute renal failure, de-
fined as 50% reduction from baseline in the GFR or a
need for dialysis treatment during the initial hospitaliza-
tion for transplantation, CsA used during initial hospital-
ization, hypertension, categorized as previous diagnosis
before transplantation, diabetes before transplantation,
hepatitis C virus seropositivity before transplantation,
1990 to 1993 as the period during which transplantation
was performed as compared to 1998 to 2000 as a reference
group.
The role of calcineurin inhibitors cannot be evaluated
by comparing it with other immunosuppressive protocols,
as no comprehensive alternative schedules are available.
One such example may be seen in the study by Ojo et al [4]
where less than 1% of recipients of all extrarenal organs
received sirolimus, with or without calcineurin inhibitors,
during pretransplant hospitalization. However, it is worth
noting that in this study patients with insufficient or in-
complete medical picture on such treatment (data not
being available at the time of initial hospitalization for
transplantation) are indicated as having a lower risk of
developing chronic renal failure (relative risk = 0.87)
(P < 0.001). And there was no association between
sirolimus therapy and chronic renal failure in the sub-
group of liver transplants. Another important expo-
nent for gauging the likelihood of renal complications is
longevity. The risk of developing chronic renal failure ap-
pears to correlate with age. This relationship, confirmed
in single-center studies performed on patients receiving
liver and heart transplants [2, 4], is in agreement with cur-
rent knowledge on renal transplantation. Kidneys from
older donors seem to be more susceptible to calcineurin
inhibitor toxicity [2].
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In conclusion, mechanisms of ESRD in nonrenal trans-
plant recipients share some common denominators (first,
calcineurin inhibitor–mediated nephrotoxicity) to which
procedure-specific, organ-specific, and patient-specific
factors have to be added.
A primary source of kidney damage in nonrenal
transplant recipients is calcineurin inhibitor–mediated
nephrotoxicity, as in renal allografts, minus the local dam-
age mediated by chronic rejection, plus the additional
damage mediated by local innervation and other organ-
specific factors (Fig. 2).
At present, it is impossible to assess to what extent cal-
cineurin inhibitor–mediated nephrotoxicity aggravates
the deterioration of renal function in renal versus non-
renal transplant recipients. Moreover, it is difficult to
stratify patients into risk factor groups of one type of
nonrenal transplant versus the others. However, a better
understanding of analogies and differences in damaging
calcineurin inhibitor mechanisms within different subsets
of patients is important in order to implement “organ-
specific” strategies for both prevention and therapy.
PREVENTION AND THERAPY STRATEGIES
Prevention of renal function loss after nonrenal solid
organ transplantation should start from a careful evalu-
ation of several preoperative, intraoperative, and post-
operative components (Table 3), before considering any
change in the immunosuppressive regimen [2, 3].
Indeed, in the presence of pretransplantation renal
function impairment it is essential to achieve an adequate
renal perfusion by the adoption of careful anesthetic and
operative techniques. Concomitant nephrotoxic drugs or
intravenous calcineurin inhibitors should also be avoided,
and early-phase calcineurin inhibitor peak levels should
be closely monitored [2, 3].
Dihydropyridine calcium antagonist and drugs block-
ing the renin-angiotensin system (both ACE inhibitors
and angiotensin II receptor antagonists) should be con-
sidered. A combination of these two categories could in
theory provide protection from both the acute hemo-
dynamic component of nephrotoxicity (through calcium
antagonist–mediated reduction of afferent arteriole vaso-
constriction [56]) and chronic vascular and tubulointer-
stitial injury (through inhibition of angiotensin II effects
with consequent reduction of TGF-b and other profi-
brotic mediators) [57, 58].
Enalapril and valsartan have been proved to be effec-
tive in restoring physiologic vasoconstriction of renal ar-
teries in response to noradrenalin and angiotensin II, as
well as relaxation response to acetylcoline and sodium
nitroprusside, after the administration of CsA in sponta-
neously hypertensive rats [59].
The role of angiotensin II–induced oxidative stress in
CsA nephrotoxicity is also emerging. Angiotensin II re-
Table 3. Preventive strategies for calcineurin inhibitor–induced
nephrotoxicity in nonrenal transplanted patients
Setting Strategy
Preoperative Thoroughly evaluate renal function
Try to identify and reduce, when possible, main
pathogenic causes of renal failure
Intraoperative Avoid renal hypoperfusion through careful fluid
management
Reduce use of catecholamines
Postoperative Treat infections and sepsis with a full and
aggressive schedule
Carefully use aminoglycosides, always
monitoring serum levels
If dialysis is needed, optimize tolerance by
avoiding hypotension and excessive
ultrafiltration, especially in patients already
on calcineurin inhibitor
When possible, delay introduction of calcineurin
inhibitor, especially in patients with acute
tubular necrosis or heart failure
Avoid intravenous administration of calcineurin
inhibitor
Monitor peak cyclosporine A levels
Long-term Treat hypertension [angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II
antagonists should be employed especially if
proteinuria is present Dihydropyridine
calcium antagonist may be useful
Treat hyperlipidemia
Limit calcineurin exposure
Consider reduction of calcineurin levels or even
its withdrawal through introduction of
alternative immunosuppressors.
ceptor antagonist candesartan cilexetil has been shown to
reduce tissue lipid peroxidation and morphologic changes
in CsA-treated rats [60].
In animal models endothelin antagonists have proved
capable of counteracting calcineurin inhibitor–induced
hemodynamic changes, but even though they can pre-
vent the decline in GFR they seem to offer no protection
against the morphologic injury [58]. Adequate control
of calcineurin inhibitor–induced hypertension is proba-
bly as important as in native kidney disease and renal
transplantation [47]. However, whether or not these pre-
ventive measures will also be able to offer clinically rele-
vant renal protection in nonrenal transplant recipients is
something which requires further study.
The priority should therefore be to minimize or com-
pletely avoid the use of calcineurin inhibitors. This sec-
tion will focus on immunosuppressive options which are
employed with ever increasing frequency to this aim.
Several protocols first tested in the setting of kidney
transplants, where organ rejection is not usually a life-
threatening event, were then applied to the area of life-
saving transplants, where a greater degree of caution has
to be respected. We will now review the state of the art of
these approaches both in kidney and in nonrenal organ
transplants.
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Lessons from calcineurin inhibitor minimization in
kidney transplants
The goal of minimizing calcineurin inhibitor nephro-
toxicity led to three approaches being attempted: cal-
cineurin inhibitor elimination, avoidance, or substitution
[61]. Every approach was based on either sirolimus or
mycophenolate mofetil (MMF) or on an association of
these two drugs [62, 63].
Elimination of CsA was achieved in an early phase
(3 months after transplantation) within a protocol, in-
cluding sirolimus, CsA, and steroids. A marked improve-
ment of renal function was observed in the subgroup of
patients that had been randomly chosen to continue a
maintenance therapy of only sirolimus and steroids at 1
year (mean calculated GFR of 57 mL/min vs. 63 mL/min)
(P < 0.001), with no significant difference in the trans-
plant outcome [64].
Both MMF [65] and sirolimus [66] were used to ei-
ther reduce or discontinue calcineurin inhibitor drugs in
chronic allograft nephropathy. Significant improvements
in renal function were observed in about 30% of patients.
The antiproliferative properties of both drugs (especially
rapamycin) and their specific inhibitory effect on fibro-
genesis make them good candidates to counteract cal-
cineurin inhibitor–induced nephrotoxicity [67, 68].
Avoidance of calcineurin inhibitor was obtained in in-
duction protocols with monoclonal antibodies, based on
the use of daclizumab, MMF, and steroids [69] or alem-
tuzumab and sirolimus monotherapy [70]. Although re-
nal function was excellent in both cases (serum creatinine
= 1.2 mg/dL at 1 year), proving the remarkable impact
of a nonnephrotoxic therapy in the initial posttransplant
phase, high rejection rates were reported.
Another way of avoiding calcineurin inhibitors can
be defined as calcineurin inhibitor substitution [71, 72].
Sirolimus can be used instead of CsA in a three-drug
maintenance regimen with an antiproliferative agent
(azathioprine or MMF) and steroids.
The prototype of this protocol was first tested by Groth
et al [71] (using azathioprine) and Kreis et al [72] (using
MMF), with excellent results in terms of renal function
(serum creatinine = 1.3 mg/dL and 1.4 mg/dL). But, once
again, elevated rejection rates were recorded (41% and
30%, respectively).
In an attempt to improve the safety of this protocol,
Flechner et al [73] developed a similar one, reinforced
with basiliximab induction (followed by sirolimus, MMF,
and steroids). When compared to a traditional protocol
with CsA, MMF, and steroids, no difference in trans-
plant outcome emerged after an average follow-up of
18 months (acute rejection rate at 1 year = 6.4% with
sirolimus and 6.7% with CsA). There was, however, a dra-
matic improvement in renal function in the calcineurin
inhibitor–free patients after the first few months, which
increased steadily over time. Samples taken at 6, 12, and
18 months showed average creatinine levels (mg/dL) for
the sirolimus patients to be 1.29, 1.32, and 1.30 while those
for CsA patients measured 1.74, 1.78, and 1.89, respec-
tively (P = 0.005).
In conclusion, on the one hand induction therapy based
on calcineurin inhibitor–sparing or calcineurin inhibitor–
free protocols with MMF and/or sirolimus contributes
to a better renal function level after 1 year, which is a
powerful predictor of long-term graft survival [74]. On
the other, both drugs appear to be effective in allow-
ing some degree of renal function recovery in chronic
allograft nephropathy. In this setting, besides having pos-
itive effects on nephrotoxicity, due to the reduction or
discontinuation of calcineurin inhibitor, their immuno-
suppressive properties have an impact on chronic re-
jection, the alloantigen-dependent process of chronic
allograft nephropathy. Therefore, they interact with both
the nonimmune and the immune component of chronic
allograft nephropathy in kidney transplant recipients.
Obviously, their effects on renal function in nonrenal
transplant recipients only allow us to cut down the use
of calcineurin inhibitors.
Calcineurin inhibitor minimization in nonrenal
organ transplants
Minimization strategies in this context rely on the same
strategies described for kidney transplants, although their
application has unique peculiarities depending on the
type of transplanted organ.
Comparison between CsA and tacrolimus has not yet
produced any sound evidence of a less nephrotoxic im-
pact of the latter [75, 76], and available data are so far
conflicting. Indeed, in pediatric heart transplant recipi-
ents [77], exposure to tacrolimus was found to increase
the independent risk of renal dysfunction, whereas in the
study by Ojo et al [4], the excess risk of chronic renal fail-
ure in liver transplant recipients was greater with CsA
therapy than with tacrolimus.
Similarly, many experiences on small samples of non-
renal organ recipients suggest that a cautious shift from
the use of calcineurin inhibitors to alternative immuno-
suppressive agents may prove a potentially advantageous
and safer approach.
Organ-specific reports
Liver. Prospective studies demonstrated that both
GFR and renal plasma flow (measured with 125I-
iothalamate and 131I-hippuran, respectively), consider-
ably improved after CsA withdrawal and stimulation with
dopamine and amino acid infusion (from 74 to 90 mL/
min) (P < 0.04) and from 310 to 380 mL min/min (P <
0.03), even after more than 2 years of CsA treatment [78].
Sirolimus has been used as the primary immunosup-
pressive agent to replace calcineurin inhibitors in cases
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of nephrotoxicity, making the reduction or complete
withdrawal of calcineurin inhibitors possible. Conversion
to sirolimus led to an improvement in renal function
in about a half of the patients, on average more than
6 months after the switch [79]. It has been used either as
a monotherapy [80] or together with low-dose tacrolimus,
resulting in exceptionally low rates of acute rejection, and
continued, excellent renal function [81–83]. In several ex-
periences MMF and azathioprine both made safe with-
drawal of CsA or tacrolimus possible [84–86]. In a recent
report by Cantarovich, Tzimas, and Barkun [84] a gradual
reduction of CsA (up to 25 mg twice daily) combined with
an introduction of MMF (1 g twice daily) determined a
significant improvement of renal function, even in long-
term transplant patients (46 ± 22 months), although a
12-month follow-up was needed to confirm these results.
Acute rejection occurred in 29% of these patients and
was steroid-responsive in all but one (the patient died
because of liver necrosis due to acute rejection caused by
noncompliance).
Heart. The first attempt to prevent calcineurin
inhibitor–induced nephrotoxicity involved the once daily
administration of CsA [87] or a concomitant treatment
with pentoxifylline [88]. In more recent studies, a strat-
egy of switching from azathioprine to MMF as well as
a reduction of CsA dosage determined a short-term im-
provement in renal function in most patients, although
both acute rejection and infections were reported within
the first 12 months after the switch [89, 90]. A study per-
formed on pediatric heart transplant recipients shows
that the nephrotoxic effect of tacrolimus and CsA are
comparable over a long term [91], while other authors
report positive effects after conversion from CsA to
tacrolimus in small samples of patients [92].
Lung. Conversion from azathioprine to MMF and a
decrease in calcineurin inhibitor doses, with subsequent
improvement of renal function (increase of GFR by 20%
after a mean follow-up of 16 ± 4 months), has been de-
scribed in lung transplant patients [93]. When sirolimus
was used on this population, a substantial decrease or
even withdrawal of calcineurin inhibitors was possible. It
is worth noting that the direction of creatinine after 30
days predicted long-term creatinine, whereas the starting
creatinine did not predict the 30-day or long-term value
[94].
Intestine. A protocol-based on tacrolimus, da-
clizumab, sacrolimus, and budesonide has been used af-
ter small bowel transplantation to reduce nephrotoxicity
[95].
CONCLUSION
Not only does chronic renal failure and ESRD signif-
icantly worsen the prognosis of nonrenal transplant pa-
tients, they are also very expensive. The risk of chronic
renal failure and the need for long-term renal replace-
ment therapy will increase, as improvements in general
care allow transplant recipients to live longer.
As these complications are relatively common, it is es-
sential that patients receive thorough counseling before
transplantation. Preventive measures should be encour-
aged, these include a careful assessment of preexisting
renal disease and chronic renal failure, improvements in
the operative and perioperative management to minimize
the risk of acute renal failure, and the identification and
correction of modifiable cardiovascular risk factors. Once
nephrotoxicity occurs, the role of the nephrologist should
not be limited to diagnosing it as the cause of posttrans-
plant chronic renal failure and of monitoring its follow-up
through periodical controls; this “wait and see” attitude
often merely results in the passive registration of a re-
lentless progression of renal damage. The nephrologists’
experience in immunosuppressive therapy should rather
be cautiously applied to the other solid organs and tissue
transplant recipients. Active strategies for optimizing cal-
cineurin inhibitor treatment should concentrate on the
association of nonnephrotoxic drugs (such as MMF and
rapamycin) and even on new induction protocols for the
delayed introduction of calcineurin inhibitors (through
the employment of monoclonal antibodies). Avoiding
their effects at an early phase can reduce the detrimental
outcome caused by concomitant factors such as hemody-
namic instability. In the near future calcineurin inhibitor–
sparing protocols might even be considered as a primary
immunosuppressive therapy, before the onset of an es-
tablished renal damage.
Their widespread use may have the potential to signif-
icantly reduce renal morbidity in the area of life-saving
transplants.
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